QOverview
Quantum-Si develops proteomics tools to analyze proteins at the single-molecule level using NGPS technology. The system uses a semiconductor chip to immobilize peptides and read amino acids in real time with fluorescent recognizers, delivering single-residue data through an end-to-end platform of instruments, prep kits, and cloud software. It differentiates itself with a semiconductor-based, integrated benchtop workflow that simplifies operation and provides detailed proteoform and post-translational modification profiling. Its goal is to accelerate drug discovery and clinical diagnostics by making protein sequencing more accessible and actionable for research, pharma, and diagnostics labs.
Work here?Claim your company
About Quantum-Si
Industries
Company Size
51-200
Company Stage
IPO
Headquarters
Branford, CT
Founded
2013
Get referred to Quantum-Si
See people who can refer or advise you
Simplify's take
What believers are saying
- Management cut 2026 cash use and OpEx to $87 million or less after August restructuring.
- Cash and marketable securities of $149.4 million fund operations into Q4 2028.
- Proteus pre-orders, 35-city roadshows, and 800-plus attendees created early commercial pull before launch.
What critics are saying
- Q3 2026 revenue fell to $212,000; customers are waiting for Proteus, not buying Platinum.
- Proteus slipped from late 2026 to Q2 2027 after variability problems and an extra design cycle.
- If Proteus underdelivers again, Quantum-Si becomes a cash-burning niche lab-tools company facing Nasdaq-delisting pressure.
What makes Quantum-Si unique
- Jonathan Rothberg’s 2013 founding and semiconductor chip platform target benchtop protein sequencing.
- Proteus showed 30x sequencing output per chamber and 1.36% false discovery rate at HUPO 2026.
- Quantum-Si combines instruments, consumables, software, and pre-orders around a razor-and-blade proteomics model.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$640M
Above
Industry Average
Funded Over
4 Rounds
Benefits
- Health Insurance
- 401(k) Retirement Plan
- 401(k) Company Match
- Real-time performance monitoring
- Remote Work Options
- Paid Vacation
- Paid Holidays
- Hybrid Work Options
- Wellness Program
- Mental Health Support
- Gym Membership
- Phone/Internet Stipend
Stock Price
Growth & Insights and Company News
6 month growth
3%1 year growth
3%2 year growth
0%Quantum-Si reported third-quarter revenue of $212,000, down from $552,000 a year earlier, as customers held back on its existing Platinum platform ahead of the Proteus launch. Net loss narrowed to $22.3 million from $35.7 million. The company still plans to launch its Proteus protein sequencing platform in the second quarter of 2027. Early testing showed about 30 times more sequencing output per chamber than Platinum Pro, though the data did not come from a fully optimised final product. Quantum-Si kept its full-year revenue outlook at about $1 million. It cut its 2026 adjusted operating expense and cash use outlook to $87 million or less for each, helped by restructuring that should save about $12 million a year. Its $149.4 million in cash and marketable securities should fund operations into the fourth quarter of 2028.
Quantum-Si Q3 earnings call highlights. Quantum-Si (NASDAQ:QSI) reported lower third-quarter revenue and narrowed its net loss as it prepared for the planned second-quarter 2027 commercial launch of its Proteus protein sequencing platform. The company reiterated its full-year revenue guidance of approximately $1 million and lowered its outlook for both adjusted operating expenses and cash usage. Management said restructuring actions implemented after their announcement in August are expected to generate approximately $12 million in annualized operating expense savings. Revenue for the quarter ended September 30 fell to $212,000 from $552,000 a year earlier. Chief Financial Officer Jeff Keyes said results reflected limited near-term capital purchases of the company's existing Platinum platform, customer awareness of the anticipated Proteus launch and commercial decisions intended to help customers transition to the new system. Net loss narrowed to $22.3 million from $35.7 million in the prior-year quarter. Adjusted EBITDA was negative $17 million, compared with negative $20.1 million a year earlier. Proteus development and pre-orders. President and CEO Jeff Hawkins said Quantum-Si remains on track to launch Proteus in the second quarter of 2027. The company added an integrated instrument design cycle after identifying variability earlier in development, and Hawkins said recent performance data indicated those issues had been substantially addressed. Design activities for the additional cycle are complete, major components have been ordered and subassemblies are being manufactured, he said. The first instruments from that build are expected during the current quarter, but Hawkins clarified during the analyst question-and-answer session that they are intended for research and development rather than sale. Quantum-Si has also started a Proteus pre-order program. Hawkins said customers placing an order with a deposit can receive preferred pricing and priority access when early access or commercial placements begin. He said the company could provide visibility into pre-orders in early 2027 and expects to place a couple of machines at customer sites for early-access work. Since launching a Proteus roadshow in April, the company has held events in more than 35 cities and reached more than 800 attendees across the United States, Canada and Europe, Hawkins said. He described prospective customer interest as a relatively even mix of existing users and new accounts. Sequencing progress. Hawkins said Quantum-Si has demonstrated detection of 19 amino acids and expects to demonstrate detection of the 20th before the end of 2026. Its commercially available sequencing kit supported 15 amino acids at the end of 2025, while an 18-amino-acid developmental kit was used to generate data presented at the World HUPO conference in September. The CEO distinguished between demonstrating detection in a research formulation and incorporating it into a kit. He said the company had not decided whether to develop a 19-amino-acid kit or wait to include the 20th, but felt it was in a strong position to have all 20 available at the Proteus launch if the remaining detection milestone is achieved. In the interim World HUPO study, developmental Proteus equipment produced approximately 30 times more sequencing output per chamber than Platinum Pro, Hawkins said. Proteus recorded a 1.36% false discovery rate versus 6.58% for Platinum Pro and identified all proteins in 10-plex and 24-plex reference mixtures. Hawkins cautioned that the conference data did not represent a fully optimized final product. He said Quantum-Si expects to provide definitive performance specifications at launch and anticipates further improvement in several measures, including peptide identification and sample complexity. The company is also incorporating artificial intelligence and machine learning into its analysis pipeline. Hawkins said the combination of AI-driven analysis and detection of all 20 amino acids could provide a path toward reference-free sequencing in 2027, though the work remains in development. Spending outlook and supply chain. Quantum-Si lowered its 2026 adjusted operating expense guidance to $87 million or less from $98 million or less. It also reduced its total cash usage outlook to $87 million or less from $93 million or less. Third-quarter GAAP operating expenses declined to $23.9 million from $40 million a year earlier, a period that included net lease termination and legal settlement expenses. Adjusted operating expenses fell to $18.2 million from $21.4 million. The company held $149.4 million in cash equivalents and marketable securities at September 30. Keyes said Quantum-Si believes it has sufficient capital to fund operations into the fourth quarter of 2028, including the activities required for the Proteus launch. Keyes said AI-related demand has lengthened lead times for some Proteus components. To address the risk, Quantum-Si is ordering parts earlier, committing volume with suppliers and, where practical, qualifying second sources and building safety stock. The purchases may modestly increase near-term working capital needs, he said, but are included in the cash outlook. Based on current information, Keyes said, the company does not expect supply chain conditions to affect the planned second-quarter 2027 launch. About Quantum-Si (NASDAQ:QSI). Quantum-Si Incorporated (NASDAQ:QSI) is a life sciences technology company focused on transforming protein analysis through next-generation proteomics. The company develops tools designed to identify and characterize proteins at the single-molecule level, with potential applications in drug discovery, translational research, diagnostics development and precision medicine. Its primary offering is the Platinum platform, which combines a benchtop sequencing instrument, semiconductor-based technology, consumables and data-analysis software.
Quantum-Si (NASDAQ:QSI) posts quarterly earnings results, beats expectations by $0.02 EPS. November 6, 2026 Key points. * Quantum-Si reported a quarterly loss of $0.10 per share, beating estimates of a $0.12 loss, but revenue of $212,000 missed the $270,000 forecast and fell from $552,000 a year earlier. * Its Proteus instrument remains on track for a second-quarter 2027 launch. The company reported encouraging interim performance and is pursuing pre-orders, but did not disclose order numbers. * Quantum-Si reiterated 2026 revenue guidance of about $1 million while lowering its adjusted operating expense and cash-use outlook to $87 million or less each. It reported $149.4 million in cash and expects funding to last into the fourth quarter of 2028. * Interested in Quantum-Si? Here are five stocks we like better. Quantum-Si (NASDAQ:QSI - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.02, FiscalAI reports. The company had revenue of $0.21 million for the quarter, compared to analysts' expectations of $0.27 million. Quantum-Si had a negative return on equity of 47.12% and a negative net margin of 6,138.26%. Here are the key takeaways from Quantum-Si's conference call: * Quantum-Si said Proteus remains on track for a second-quarter 2027 launch. It reported that instrument design is complete, variability issues are substantially addressed, and manufacturing of the next development build is underway, with initial instruments expected this quarter. * The company has demonstrated detection of 19 amino acids and expects to demonstrate the 20th by year-end, with all 20 targeted for launch. At World HUPO, interim Proteus results showed about 30 times more sequencing output per chamber than Platinum Pro and a lower false discovery rate, though management said the product is still in development. * Quantum-Si has held Proteus Roadshow events in more than 35 cities and launched a pre-order program offering priority access and pricing. Management described prospective-customer interest as encouraging and said the sales funnel includes both existing users and new accounts, but did not disclose order numbers. * Revenue fell to $212,000 from $552,000 year over year in the quarter, and the company reiterated full-year 2026 revenue guidance of about $1 million as customers await Proteus. Quantum-Si reported $149.4 million in cash, equivalents and marketable securities and said it expects funding to last into the fourth quarter of 2028. * The company lowered its 2026 adjusted operating expense outlook to $87 million or less from $98 million or less and cash-use outlook to $87 million or less from $93 million or less, citing cost actions and discipline. It is also ordering long-lead components earlier amid AI-related supply constraints, which may increase near-term working capital needs; management said it does not currently expect the constraints to affect the launch timeline. Quantum-Si stock up 13.7%. NASDAQ:QSI traded up $0.16 on Friday, reaching $1.33. 8,206,582 shares of the stock traded hands, compared to its average volume of 9,981,961. Quantum-Si has a 12 month low of $0.69 and a 12 month high of $1.81. The company's fifty day simple moving average is $1.08 and its 200 day simple moving average is $0.97. Analyst upgrades and downgrades. Several research firms recently commented on QSI. Weiss Ratings raised shares of Quantum-Si from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, September 24th. Alliance Global Partners reiterated a "buy" rating on shares of Quantum-Si in a report on Friday, August 14th. HC Wainwright set a $4.00 price target on Quantum-Si in a research report on Friday, October 9th. Finally, Wall Street Zen raised Quantum-Si from a "sell" rating to a "hold" rating in a research report on Tuesday, October 27th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $2.50. Discover more Stock research tools Financial portfolio tracker About Quantum-Si. Quantum-Si Incorporated NASDAQ: QSI is a life sciences technology company focused on transforming protein analysis through next-generation proteomics. The company develops tools designed to identify and characterize proteins at the single-molecule level, with potential applications in drug discovery, translational research, diagnostics development and precision medicine. Its primary offering is the Platinum platform, which combines a benchtop sequencing instrument, semiconductor-based technology, consumables and data-analysis software. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Quantum-Si, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quantum-Si wasn't on the list. While Quantum-Si currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Continue following MarketBeat
Quantum-Si Q3 revenue falls 62 percent as firm focuses on R&D. November 05, 2026 07:08 PM EST NEW YORK - Proteomics firm Quantum-Si reported Thursday afternoon that its third quarter revenue fell 62 percent compared to the year-ago period as the firm focuses on developing its new protein sequencing platform. Get the full story with GenomeWeb Premium. Premium Access Trial - only $95 for the first 90 days
Quantum-Si (QSI) set to release earnings on Thursday. October 29, 2026 Quantum-Si (NASDAQ:QSI - Get Free Report) is projected to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Quantum-Si to post earnings of ($0.13) per share and revenue of $0.27 million for the quarter. Investors are encouraged to explore the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET. Quantum-Si (NASDAQ:QSI - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). The company had revenue of $0.34 million during the quarter, compared to the consensus estimate of $0.30 million. Quantum-Si had a negative net margin of 6,138.26% and a negative return on equity of 47.12%. On average, analysts expect Quantum-Si to post ($0.47) EPS for the current fiscal year and ($0.42) EPS for the next fiscal year. Quantum-Si trading up 4.2%. Shares of QSI opened at $1.72 on Thursday. The firm has a market cap of $376.48 million, a price-to-earnings ratio of -3.74 and a beta of 3.21. Quantum-Si has a 52 week low of $0.69 and a 52 week high of $2.23. The stock has a 50 day moving average of $1.01 and a 200-day moving average of $0.96. Analysts set new price targets. A number of research analysts have recently issued reports on QSI shares. Wall Street Zen upgraded shares of Quantum-Si from a "sell" rating to a "hold" rating in a research report on Tuesday. Alliance Global Partners reissued a "buy" rating on shares of Quantum-Si in a report on Friday, August 14th. HC Wainwright set a $4.00 price objective on Quantum-Si in a research report on Friday, October 9th. Finally, Weiss Ratings upgraded Quantum-Si from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, September 24th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Quantum-Si currently has a consensus rating of "Hold" and a consensus price target of $2.50. Quantum-Si company profile. Quantum-Si Incorporated NASDAQ: QSI is a life sciences technology company focused on transforming protein analysis through next-generation proteomics. The company develops tools designed to identify and characterize proteins at the single-molecule level, with potential applications in drug discovery, translational research, diagnostics development and precision medicine. Its primary offering is the Platinum platform, which combines a benchtop sequencing instrument, semiconductor-based technology, consumables and data-analysis software. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Quantum-Si, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quantum-Si wasn't on the list. While Quantum-Si currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets. Continue following MarketBeat
Quantum-Si is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
About Quantum-Si
Industries
Company Size
51-200
Company Stage
IPO
Headquarters
Branford, CT
Founded
2013
Quantum-Si is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs